Relationship Between PTEN and Livin Expression and Malignancy of Renal Cell Carcinomas

  • Cheng, Tao (Department of Urology, the 1st Affiliated Hospital of He'nan University of Science and Technology) ;
  • Zhang, Jian-Guo (Department of Urology, the 1st Affiliated Hospital of He'nan University of Science and Technology) ;
  • Cheng, Yuan-He (Department of Urology, the 1st Affiliated Hospital of He'nan University of Science and Technology) ;
  • Gao, Zhong-Wei (Department of Urology, the 1st Affiliated Hospital of He'nan University of Science and Technology) ;
  • Ren, Xiao-Qiang (Department of Urology, the 1st Affiliated Hospital of He'nan University of Science and Technology)
  • Published : 2012.06.30


Objectives: This study focused on PTEN and Livin expression and associations with malignancy in human renal clear cell carcinomas (RCCC). Methods: PTEN and Livin expression was assessed in 100 RCCC tissue samples, 50 paracarcinoma cases, and 20 normal renal tissue samples using the immunohistochemical Streptavidin proxidase (SP) method. The relationships between binding and corresponding biological characteristics, such as histological grade, lymph node metastases, and clinical stages were analyzed. Results: Positive PTEN expression in RCCC was significantly lower than in renal tissue adjacent to carcinoma tissue and normal renal tissue (P<0.01). Livin expression in the renal tissue adjacent to the carcinoma and normal renal tissues exhibited only low levels, whereas overall Livin expression in RCCC was statistically significant (P<0.01). In RCCC, PTEN expression rate gradually decreased with an increase in clinical stage, whereas that of Livin increased to statistically significant levels (P<0.01), PTEN and Livin levels being negatively correlated (r=-0.395, P<0.01). Conclusions: PTEN and Livin are important in RCCC development. The two factors combined are expected to provide indices for estimating RCCC malignancy and progression levels, as well as references for RCCC diagnosis and treatment.


  1. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D (2001). Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett, 495, 56-60.
  2. Brenner W, Färber G, Herget T, et al (2002). Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Canaer, 99, 53-7.
  3. Feng Y, Tian ZM, Wan MX, Zheng ZB (2008). Low intensity ultrasound-induced apoptosis in human gastric carcinoma cells. World J Gastroenterol, 14, 4873-9.
  4. Gangar SC, Koul A (2008). Histochemical, ultrastructural, and biochemical evidences for Azadirachta indica-induced apoptosis in benzo(a)pyrene-induced murine forestomach tumors. J Environ Pathof Toxicol Oncol, 27, 219-32.
  5. Hager M (2007). PTEN expression in renal cell carcinoma and progonosis. Pathology, 39, 482-5.
  6. Huang J, Kontos CD (2002). Moddulates vaseular endotheliad growth factor-mediated signaling and angiogenic effects. J Biol Chem, 277, 10760-6.
  7. Ka H, Hunt JS (2003). Temporal and spatial patterns of expression of inhibitors of apoptosis in human placentas. Am J Pathol, 163, 413-22.
  8. Kasof GM, Gomes BC (2001). Livin, a novel inhibitor of apoptosis protein Family member. J Biol Chem, 276, 3238-46.
  9. Li DM, Sun H (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosin ephosphates regulated by transforming growth factor ${\beta}$. Cancer Res, 57, 2124-9.
  10. Li RH (2009). Livin and PTEN in colorectal cancer tissues and its significance. Chin J integrated traditional and Western Med, 16, 247-8.
  11. Nachmias B, Mizrahi S, Elmalech M, et al (2007). Manipulation of NK cytotoxicitv by the IAP family member Livin. Eur J Immunol, 37, 3467-6.
  12. Ni JH, Xin J, Wu BC, Xin MH, Wu WF (2011). Livin and PTEN in renal cell carcinoma and its clinical significance. Practical J Cancer, 26, 42-4.
  13. Rasheed BK, Stenzel TT, Melendon RE, et al (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res, 57, 4187-90.
  14. Sui CD, Miao B (2009). PTEN and Livin in tongue squamous cell carcinoma and its clinical significance. Heilongjiang Pharmaceutical Science, 32, 26-7.
  15. Sun CH, Chang YH, Pan CC (2011). Activation of the p13k/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Hisopathologh, 58, 1054-63.
  16. Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N (2004). Expression of survivin mRNA and Livin mRNA in non-small-cell lung cancer. Lung Cancer, 46, 299-304.
  17. Trotman LC, Wang X, A1imonti A, et al (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell, 128, 141-56.
  18. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM (2000). LIVIN, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol, 10, 1359-66.
  19. Xu ST, Yan CY, Huang YH, Ding X (2010). Research on expression of livin in human renal cell carcinoma. Med J West China, 22, 217-9.
  20. Zhang Q, Gao Y, Wang XL, et al (2010). In esophageal squamous cell carcinoma tissue PTEN, Livin changes in protein expression and significance. Shandong Med J, 50, 52-3.
  21. Zhao Y, Deng X, Wang Q (2009). Livin, Smac/DIABLO in stomach tissue PTEN and expression and the correlation and gastric cancer. World Chinese J Digestol, 17, 1303-11.

Cited by

  1. Expression and Clinical Significance of Livin Protein in Hepatocellular Carcinoma vol.35, pp.1875-8630, 2013,
  2. Association of the PTEN IVS4 (rs3830675) Gene Polymorphism with Reduced Risk of Cancer: Evidence from a Meta-analysis vol.16, pp.3, 2015,
  3. MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN vol.13, pp.6, 2016,